SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection

Press Release SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection Pathlight is a tumor-informed, multi-cancer MRD platform with its first indication in breast cancer Published, peer-reviewed clinical study demonstrates 100% sensitivity, 100% specificity, and a 13.7-month lead time to recurrence across all subtypes […]